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ABSTRACT
Objectives: The global obesity epidemic has great impact on the prevalence of low-grade 
endometrial carcinoma. The preoperative tumor serum marker cancer antigen 125 (CA-125) 
might contribute to improved identification of high-risk patients within this group. The study 
aimed to investigate the prognostic value of CA-125 in relation to established preoperative 
prognosticators, with a focus on identifying patients with poor outcome in low-grade 
endometrial carcinoma (EC) patients.
Methods: Prospective multicenter cohort study including all consecutive patients surgically 
treated for endometrial carcinoma in nine collaborating hospitals from September 2011 until 
December 2013. All preoperative histopathological diagnoses were reviewed in a blinded manner. 
Associations between CA-125 and clinicopathological features were determined. Univariable 
and multivariable analysis by Cox regression were used. Separate analyses were performed for 
preoperatively designated low-grade and high-grade endometrial carcinoma patients.
Results: A total of 333 patients were analyzed. CA-125 was associated with poor prognostic 
features including advanced International Federation of Gynecology and Obstetrics (FIGO) 
stage. In multivariable analysis, age, preoperative tumor and CA-125 were significantly 
associated with disease-free survival (DFS); preoperative grade, tumor type, FIGO and CA-125 
were significantly associated with disease-specific survival (DSS). Low-grade EC patients with 
elevated CA-125 revealed a DFS of 80.6% and DSS of 87.1%, compared to 92.1% and 97.2% in 
low-grade EC patients with normal CA-125.
Conclusion: Preoperative elevated CA-125 was associated with poor prognostic features and 
independently associated with DFS and DSS. Particularly patients with low-grade EC and 
elevated CA-125 represent a group with poor outcome and should be considered as high-risk 
endometrial carcinoma.
J Gynecol Oncol. 2019 Sep;30(5):e70
https://doi.org/10.3802/jgo.2019.30.e70
pISSN 2005-0380·eISSN 2005-0399
Original Article
Received: Jan 2, 2019
Revised: Jan 30, 2019
Accepted: Feb 24, 2019
Correspondence to
Casper Reijnen
Department of Obstetrics and Gynaecology, 
Radboud University Medical Center, Geert 
Grooteplein 10, 6525 GA, Nijmegen, The 
Netherlands.
E-mail: Casper.reijnen@radboudumc.nl
Copyright © 2019. Asian Society of 
Gynecologic Oncology, Korean Society of 
Gynecologic Oncology
This is an Open Access article distributed 
under the terms of the Creative Commons 
Attribution Non-Commercial License (https://
creativecommons.org/licenses/by-nc/4.0/) 
which permits unrestricted non-commercial 
use, distribution, and reproduction in any 
medium, provided the original work is properly 
cited.
ORCID iDs
Casper Reijnen 
https://orcid.org/0000-0001-6873-7832
Nicole CM Visser 
https://orcid.org/0000-0003-3919-3922
Jenneke C Kasius 
https://orcid.org/0000-0002-9631-1422
Dorry Boll 
https://orcid.org/0000-0002-5339-8505
Peggy M Geomini 
https://orcid.org/0000-0002-1951-1076
Huy Ngo 
https://orcid.org/0000-0001-6206-1624
Dennis van Hamont 
https://orcid.org/0000-0001-5928-3269
Casper Reijnen ,1,2 Nicole CM Visser ,3 Jenneke C Kasius ,4 Dorry Boll ,5 
Peggy M Geomini ,6 Huy Ngo ,7 Dennis van Hamont ,8 Brenda M Pijlman ,9 
Maria Caroline Vos ,10 Johan Bulten ,3 Marc PLM Snijders ,2 
Leon FAG Massuger ,1 Johanna MA Pijnenborg  1
1 Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands
2Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands
3Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
4Centre of Gynaecologic Oncology Amsterdam, Academic Medical Center, Amsterdam, The Netherlands
5Department of Obstetrics and Gynaecology, Catharina Hospital, Eindhoven, The Netherlands
6Department of Obstetrics and Gynaecology, Màxima Medical Centre, Veldhoven, The Netherlands
7Department of Obstetrics and Gynaecology, Elkerliek Hospital, Helmond, The Netherlands
8Department of Obstetrics and Gynaecology, Amphia Hospital, Breda, The Netherlands
9Department of Obstetrics and Gynaecology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands
10Department of Obstetrics and Gynaecology, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands
Improved preoperative risk 
stratification with CA-125 in low-grade 
endometrial cancer: a multicenter 
prospective cohort study
Brenda M Pijlman 
https://orcid.org/0000-0003-1449-3726
Maria Caroline Vos 
https://orcid.org/0000-0002-1612-0395
Johan Bulten 
https://orcid.org/0000-0002-8168-6045
Marc PLM Snijders 
https://orcid.org/0000-0002-2434-7442
Leon FAG Massuger 
https://orcid.org/0000-0002-1539-8985
Johanna MA Pijnenborg 
https://orcid.org/0000-0002-6138-1236
Conflict of Interest
No potential conflict of interest relevant to this 
article was reported.
Author Contributions
Conceptualization: R.C., V.N.C.M., K.J.C., 
S.M.P.L.M., M.L.F.A.G., P.J.M.A. Data curation: 
R.C., V.N.C.M., K.J.C. Formal analysis: R.C., 
V.N.C.M., K.J.C., S.M.P.L.M., M.L.F.A.G., 
P.J.M.A., B.D., V.M.C. Investigation: R.C., 
V.N.C.M., K.J.C., S.M.P.L.M., M.L.F.A.G., 
P.J.M.A., B.D., V.M.C. Methodology: R.C., 
V.N.C.M., K.J.C., B.J., S.M.P.L.M., M.L.F.A.G., 
P.J.M.A., B.D., V.H.D., P.B.M., V.M.C. Project 
administration: R.C., B.J. Supervision: K.J.C., 
S.M.P.L.M., M.L.F.A.G., P.J.M.A. Validation: 
R.C., K.J.C., B.J., S.M.P.L.M., M.L.F.A.G., 
P.J.M.A., B.D., V.H.D., P.B.M., V.M.C. Writing 
- original draft: R.C., V.N.C.M., B.J., P.J.M.A. 
Writing - review & editing: R.C., V.N.C.M., 
K.J.C., B.J., S.M.P.L.M., M.L.F.A.G., P.J.M.A., 
B.D., G.P.M., N.H., V.H.D., P.B.M., V.M.C.
Keywords: CA-125 Antigen; Endometrial Neoplasms; Low-grade Carcinoma; Biomarkers; 
Risk Stratification
INTRODUCTION
Endometrial cancer (EC) is the most prevalent malignancy in industrialized countries, 
accounting for about 317.000 new cases in 2012 [1,2]. Incidence is rising, and with up to 81% 
of EC patients being obese, the global obesity epidemic is one of the leading causes of this 
increasing incidence [2-5]. Obesity mainly leads to low-grade endometrioid endometrial 
carcinomas (EECs) [3]. Low-grade EEC patients, i.e., grade 1–2, bear around 7% risk of 
disease-related mortality [6]. On the other hand, patients with high-grade EC, i.e., grade 3 
EEC and non-endometrioid endometrial carcinoma (NEEC) bear a 35% risk of disease-related 
mortality [6-9]. Although the 7% of patients with disease-related mortality in low-grade EEC 
is limited, actual numbers are numerous due to the fact that around 80% of patients present 
with low-grade EEC. Because a substantial number of disease-related mortality occur in this 
patient group, improved pre-operative risk stratification to select those low-grade patients 
with poor outcome is crucial [6-9]. In addition to preoperative tumor grade, myometrial 
invasion (MI) and tumor size, which can be assessed by ultrasound or magnetic resonance 
imaging (MRI), are important prognosticators in the preoperative risk stratification [10,11].
Although the clinical value of cancer antigen 125 (CA-125) in the work-up of EC is questioned 
in the European Society for Medical Oncology-European Society of Gynaecological Oncology-
European Society for Radiotherapy and Oncology consensus guidelines, the Society of 
Gynecologic Oncology guidelines state that CA-125 measurement can be considered in 
patients with obesity or co-morbidity that are not fit enough for comprehensive staging 
[12,13]. Moreover, CA-125 has been incorporated in the preoperative prediction model 
developed by the Korean Gynecologic Oncology Group, adequately identifying EC patients 
with a normal CA-125 with a low risk (<4%) of lymph node metastasis [14,15]. In the current 
prospective study, we evaluated the prognostic value of CA-125 in relation to established 
preoperative prognosticators in a large comprehensive cancer region, with a focus on 
identification of patients with poor outcome in clinically early-stage low-grade EEC patients.
MATERIALS AND METHODS
1. Patients
From September 1st 2011 until December 1st 2013, 432 consecutive endometrial carcinoma patients 
who underwent surgical treatment at one of the nine participating hospitals in the Netherlands 
were prospectively included in the PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) 
study [16]. Except for two centers, the preoperative work-up was standardized. CA-125 testing 
was advised in all patients. In patients with preoperative low-grade carcinomas, an additional 
abdominal computed tomography (CT)-scan was performed when CA-125 was elevated. In patients 
with preoperative high-grade carcinomas, abdominal CT-scanning was performed in all patients, 
regardless of CA-125 level. According to the Dutch guidelines, surgical staging including lymph 
node dissection in clinical stage I endometrioid type EC is recommended only in case of clinical 
suspicion of lymph node metastasis or in case of preoperative high-risk histology (i.e., serous and 
clear cell carcinomas). Patients without preoperative CA-125 test result were excluded from analysis. 
The study design followed the reporting of observational studies in epidemiology statement.
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2. Data collection
Patient characteristics, including body mass index (BMI), menopausal status, parity, CA-125 
level and CT-findings were prospectively collected. Preoperative and postoperative pathology 
data included histological grade and type, MI, cervical invasion, lymph node metastasis and 
International Federation of Gynecology and Obstetrics (FIGO) stage. All preoperative biopsy 
and hysterectomy slides were reviewed by a pathologist with special interest in gynecologic 
pathology (NV), blinded for patient characteristics and outcome. In case of discrepancy with 
the original diagnosis the case was evaluated independently by a second pathologist (JB). 
Discrepancies were resolved at simultaneous consultation. Low-grade carcinomas comprised 
grade 1 or 2 EECs, high-grade carcinomas comprised grade 3 EECs and NEECs, including 
serous, clear cell, undifferentiated carcinomas and carcinosarcomas. Patients with proven 
carcinoma in the hysterectomy specimen, but with a preoperative diagnosis of complex 
atypical hyperplasia were considered as preoperatively low-grade. Follow-up data, including 
the presence of recurrence, overall and disease-specific survival (DSS) rate, were collected. 
Preoperative CA-125 serum levels were determined by radioimmunoassay according to the 
local protocol in the various hospitals.
3. Statistical analysis
Clinicopathological differences between subgroups were compared using the χ2 and Fisher's 
exact tests for categorical data and the Mann-Whitney Utest for continuous variables. CA-
125 was analyzed as a dichotomous value, with a cut-off value of 35 IU/mL. The association 
between prognostic features and disease-free survival (DFS) and DSS was determined using 
Cox regression analysis. Features identified by univariable regression analysis with p<0.20, 
were used for multivariable regression analysis. DFS was defined as the length of time, after 
completing primary treatment, during which women survived without any clinical sign 
of disease recurrence. DSS was calculated from the date of primary treatment to the date 
of death caused by the disease or, for surviving patients, to the date of the last follow-up. 
Kaplan-Meier curves for DFS and DSS were generated, for both preoperatively classified 
low-grade and high-grade patients, comparing patients with normal and elevated CA-125 
using the Log-rank test. The p-values less than 0.05 were considered to indicate a significant 
difference. SPSS version 22 (SPSS IBM, New York, NY, USA) statistical software was used to 
perform the statistical analyses.
4. Ethical approval
This study is revised by the local medical ethical committee of the Elisabeth-Tweesteden 
Hospital Tilburg on 11 May 2011 and was exempt from Institutional Review Board (IRB) 
approval (Protocol 1129, METC, ETZ, Tilburg). This was due to the fact that this was an 
observational study without subjecting patients to specific procedures. All patients did not 
object against using their clinical data or tumor material, according to the Dutch law no 
further patient approval was needed.
RESULTS
1. Patients
A total of 432 consecutive patients with EC were included in the PIPENDO study 
(Supplementary Fig. 1). One patient with a double endometrial and ovarian tumor was 
excluded after revision, because uterine origin could not be ascertained. A total of 333 
patients underwent CA-125 serum testing (77.3%) and were included for analysis. Of the 
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excluded patients, 42 patients did not undergo CA-125 serum testing, as they were treated 
in one of the two centers that had not implemented this into their local guideline yet, and 
57 patients did not undergo testing despite stated in their guideline. Excluded cases were 
not statistically different from the study cohort with respect to variables as shown in Table 1 
(data not shown). The median age was 66 (range: 41–89). Revised preoperative diagnosis 
consisted of low-grade EC in 240 (72.1%) and high-grade EC in 93 patients (27.9%). CT-scan 
was performed in 149 patients and was suspicious for extra-abdominal disease in 29 patients 
(19.5%). Lymphadenectomy was performed in 73 patients (21.9%). The distribution of FIGO 
stage was I in 275 patients (82.6%) and stage II–IV in 58 patients (17.4%). Sixty-three patients 
(18.9%) developed recurrent disease during follow-up and 43 patients (12.9%) died as a 
consequence of the disease.
2. Preoperative prognosticators
The associations between clinicopathological features and CA-125 in patients with low-grade 
and high-grade EC are shown in Table 1. In patients with low-grade EC, CA-125 was normal 
in 177 patients (73.8%, median level 17 IU/mL, range: 3–34 IU/mL) and elevated in 63 patients 
(26.3%, median level 66 IU/mL, range: 35–1,200 IU/mL). In patients with high-grade EC, 
CA-125 was normal in 59 patients (63.4%, median level 18 IU/mL, range: 2–34 IU/mL), and 
elevated in 34 patients (36.6%, median level 58 IU/mL, range: 36–210 IU/mL). In both patients 
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Table 1. Baseline characteristics of patients with low-grade and high-grade EC, in association with CA-125 level
Characteristic Low-grade EC* High-grade EC*
CA-125 normal (n=177) CA-125 elevated (n=63) p CA-125 normal (n=59) CA-125 elevated (n=34) p
Age (yr) 65 (43.0–89.0) 68 (41.0–85.0) 0.050 68 (48.0–88.0) 71 (52.0–89.0) 0.252
BMI (kg/m2) 29 (19.0–50.0) 30 (20.0–50.0) 0.769 27 (20.0–45.0) 26 (16.0–40.0) 0.831
Follow-up (mo) 41.5 (0.0–62.0) 40.3 (1.0–64.0) 0.759 34 (0.0–60.0) 16.7 (2.0–66.0) 0.002
CA-125 (IU/mL) 17 (3–34) 66 (35–1,200) <0.001 18 (2–34) 58 (36–210) <0.001
FIGO <0.001 0.003
I–II 173 (97.7) 52 (82.5) 52 (88.1) 21 (61.8)
III–IV 4 (2.3) 11 (17.5) 7 (11.9) 13 (38.2)
Lymph nodes 0.007 0.006
Metastasis 0 (0.0) 6 (9.5) 4 (7.1) 7 (20.6)
No metastasis 13 (7.3) 8 (12.7) 28 (47.5) 7 (20.6)
Not sampled 164 (92.7) 49 (77.8) 27 (45.8) 20 (58.8)
MI <0.001 0.005
<50% 113 (63.8) 19 (30.2) 35 (59.3) 10 (29.4)
≥50% 64 (36.2) 44 (69.8) 24 (40.7) 24 (70.6)
Adjuvant treatment <0.001 0.136
No 118 (66.7) 21 (33.3) 25 (42.4) 6 (17.6)
Radiotherapy 54 (30.5) 33 (52.4) 22 (37.3) 16 (47.0)
Chemotherapy 4 (2.3) 5 (7.9) 12 (20.3) 11 (32.4)
Other 1 (0.6) 4 (6.3) 0 (0.0) 1 (2.9)
Recurrence 0.013 0.004
Yes 14 (7.9) 12 (19.4) 17 (28.8) 20 (58.8)
Local 7 (4.0) 3 (4.8) 5 (8.5) 6 (17.6)
Regional 0 (0.0) 3 (4.8) 4 (6.8) 7 (20.6)
Distant 10 (5.6) 9 (14.3) 15 (25.4) 14 (41.2)
No 163 (92.1) 50 (80.6) 42 (71.2) 14 (41.2)
Death 0.010 0.003
No 162 (91.5) 56 (88.9) 40 (67.8) 11 (32.4)
Yes 15 (8.5) 8 (12.9) 19 (32.2) 22 (64.7)
EC-related 5 (2.8) 7 (11.1) 13 (22.0) 18 (52.9)
Values are presented as median (range) or number (%).
BMI, body mass index; CA-125, cancer antigen 125; CT, computed tomography; EC, endometrial carcinoma; EEC, endometrioid endometrial carcinoma; FIGO, 
International Federation of Gynecology and Obstetrics; MI, myometrial invasion; NEEC, non-endometrioid endometrial carcinoma.
*Based on preoperative histological findings.
with high-grade and low-grade EC, elevated CA-125 was significantly associated with poor 
prognostic features including advanced FIGO stage, deep MI and lymph node metastasis, 
as well as poor outcome including recurrence and disease-related mortality. Most patients 
recurred either at regional or distant sites, and only a minority experienced a local recurrence.
As preoperative prognostic features were included age, BMI, preoperative tumor grade, 
tumor type and CA-125 serum level. As shown in Table 2, age, preoperative tumor grade, 
tumor type and CA-125 were significantly associated with DFS in univariable analysis by 
Cox regression. In multivariable analysis age, preoperative tumor grade and CA-125 were 
significantly associated with DFS.
As shown in Table 3, preoperative tumor grade, tumor histology and CA-125 were 
significantly associated with DSS in univariable analysis by Cox regression. In multivariable 
analysis preoperative tumor grade, tumor type and CA-125 were independently associated 
with DSS.
Multivariable analysis was subsequently performed with both preoperative and postoperative 
prognosticators, including MI, FIGO stage and the presence of lymphovascular space 
invasion (LVSI). CA-125 remained independently associated with both DFS and DSS 
(Supplementary Tables 1 and 2).
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Table 2. Univariable and multivariable analysis of preoperative clinicopathological parameters as prognosticators 
of DFS
DFS Univariable Multivariable
HR (95% CI) p HR (95% CI) p
Age (yr)
≤65–>65 1.94 (1.15–3.29) 0.014 1.76 (1.01–3.04) 0.044
BMI (kg/m2)
≤30–>30 0.66 (0.38–1.12) 0.132 0.74 (0.43–1.30) 0.297
Grade*
Low–High 5.22 (3.14–8.68) <0.001 3.39 (1.57–7.25) 0.002
Histology*
EEC–NEEC 4.70 (2.84–7.78) <0.001 1.87 (0.88–4.01) 0.106
CA-125
Normal–Elevated 3.02 (1.83–4.97) <0.001 3.62 (2.15–6.09) <0.001
BMI, body mass index; CA-125, cancer antigen 125; CI, confidence interval; DFS, disease-free survival; EEC, 
endometrioid endometrial carcinoma; NEEC, non-endometrioid endometrial carcinoma; HR, hazard ratio.
*Based on preoperative histological findings.
Table 3. Univariable and multivariable analysis of preoperative clinicopathological parameters as prognosticators 
of DSS
DSS Univariable Multivariable
HR (95% CI) p HR (95% CI) p
Age (yr)
≤65–>65 1.81 (0.97–3.40) 0.063 1.44 (0.77–2.72) 0.109
BMI (kg/m2)
≤30–>30 0.68 (0.35–1.32) 0.249 NA -
Grade*
Low–High 8.58 (4.40–16.75) <0.001 4.60 (1.80–11.74) 0.001
Histology*
EEC–NEEC 7.33 (4.00–13.40) <0.001 2.44 (1.05–5.70) 0.039
CA-125
Normal–Elevated 3.93 (2.15–7.22) <0.001 4.18 (2.26–7.72) 0.002
BMI, body mass index; CA-125, cancer antigen 125; CI, confidence interval; DSS, disease-specific survival; EEC, 
endometrioid endometrial carcinoma; NA, not applicable; NEEC, non-endometrioid endometrial carcinoma; HR, 
hazard ratio; TS, tumor size.
*Based on preoperative histological findings.
3. Outcome based on preoperative tumor grade
In patients with preoperative low-grade EEC, elevated CA-125 was significantly associated 
with advanced FIGO stage, deep MI, recurrence and disease-related mortality (Table 1). When 
CA-125 was normal, 14 patients (7.9%) experienced recurrence and 5 patients (2.8%) died due 
to disease, compared to 12 patients (19.4%, p=0.028) and 7 patients (11.1%, p=0.011) when 
CA-125 was elevated (Fig. 1).
In patients with preoperative high-grade EC, elevated CA-125 was significantly associated 
with advanced FIGO stage, deep MI, recurrence and disease-related mortality (Table 1). When 
CA-125 was normal, 17 patients (28.8%) experienced recurrence and 13 patients (22.0%) died 
due to disease, compared to 20 patients (58.8%, p<0.001) and 18 patients (52.9%, p<0.001) 
when CA-125 was elevated (Fig. 1).
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Fig. 1. Kaplan-Meier survival analyses for DSS (A) and DFS (B) in low-grade patients, and DSS (C) and DFS (D) in high-grade patients according to preoperative 
serum CA-125 levels. 
CA-125, cancer antigen 125; DFS, disease-free survival; DSS, disease-specific survival; EEC, endometrioid endometrial carcinoma; NEEC, non-endometrioid 
endometrial carcinoma.
DISCUSSION
Improved preoperative risk stratification is crucial in the worldwide increasing incidence 
of EC [2-5]. In the current prospective multicenter study we have demonstrated that 
elevated preoperative CA-125 is associated with several poor prognostic features, and is 
an independent prognosticator for reduced DFS and DSS. Separate analyses have shown 
that patients with low-grade EC and elevated CA-125 had a significantly lower DFS and 
DSS compared to patients with low-grade EC and normal CA-125 and therefore should be 
considered as high-risk endometrial carcinoma. Whether adjuvant treatment should be 
applied in these high-risk patients needs to be determined.
The study strengths are that it comprises a large-scale prospective, multicenter study 
cohort including all consecutively treated patients with EC within a regional network of 
collaborating hospitals [16]. A second strength is that all preoperative and postoperative 
histology was reviewed by a pathologist with special interest in gynecologic pathology, 
blinded for patient characteristics and outcome. Third, this study evaluates CA-125 
expression across subgroups, providing information about the value of CA-125 in addition to 
histology-based risk stratification. As a consequence, an additional subgroup is identified 
that should be considered as high-risk. Finally, this study focuses on preoperative markers, 
analyzing what factors contribute to risk stratification in a preoperative setting. A limitation 
of this study included the fact that 22.7% of patients were excluded because of lack of 
preoperative CA-125 testing. However, these patients did not differ from the studied group. 
Furthermore, histopathological data on lymph node status is limited, because — due to 
national guidelines — lymphadenectomy is only performed in a selective population. 
However, based on existing data, routine lymphadenectomy in early-stage low-grade patients 
has no beneficial effect on survival, and results in an increased surgical related morbidity. On 
the contrary, a substantial number of patients with lymph node metastasis in low-grade EC is 
currently missed as demonstrated by the poor outcome in a selected group [17].
Currently, for the preoperative identification of low-grade patients as high-risk, assessment 
of MI and tumor size are recommended in international guidelines [12,13]. However, in 
a preoperative or intraoperative setting, the assessment of deep MI by MRI, transvaginal 
ultrasound or frozen section is accompanied with several challenges. Regarding assessment 
of deep MI by transvaginal ultrasound, sensitivity and specificity are 82% and 81%, 
respectively; for MRI, sensitivity and specificity are 82% and 86%, reflecting only moderate 
diagnostic performance [18,19]. Moreover, moderate inter-observer agreement is reported 
for both ultrasound (k-value: 0.45–0.58) and MRI (k-value: 0.39) [20,21]. For intra-operative 
assessment of MI by frozen section, sensitivity and specificity are high: 85% and 97%, 
respectively [22]. However, time constraints and costs of performance should be taken into 
account when performing this procedure. Because preoperative assessment of serum CA-125 
level is easily accessible compared to imaging techniques and interpretation does not require 
high-level expertise, it could be an attractive alternative for measurement of MI or tumor size 
to preoperatively identify high-risk patients.
CA-125 was elevated in 29.1% of patients, comparable to earlier studies showing 11%–34% of 
EC patients revealing elevated CA-125 serum levels [23-26]. In our study, elevated CA-125 was 
associated with poor prognostic features including advanced FIGO stage, deep MI and lymph 
node metastasis. On the contrary, no association was found with preoperative tumor grade 
and our results demonstrated that elevated CA-125 was associated with poor outcome in both 
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low-grade and high-grade EC. Although no association was found with preoperative tumor 
grade, other studies did find associations with postoperative tumor grade [23,27]. This could 
be contributed to the finding that preoperative assessment of tumor grade is discordant with 
postoperative tumor grade in 33%, and in 8% a discordance between preoperative low-grade 
and surgical high-grade exists [28].
In multivariable analysis analyzing variables that are available before surgery, age >65, high tumor 
grade and elevated CA-125 were associated with reduced DFS; high tumor-grade, NEEC-histology 
and elevated CA-125 were associated with reduced DSS. Among the strongest prognosticators for 
lymph node metastasis is the presence of LVSI [29-31]. However, assessment of LVSI is based on 
histological examination of the surgical uterine specimen, and thus cannot be reliably determined 
preoperatively. Instead, preoperative clinical markers, such as age, preoperative tumor grade and 
CA-125 serum levels could be used in patient counseling and informed decision making.
In addition, preoperative immunohistochemical biomarkers have been subjected to extensive 
research [32]. Of these biomarkers, immunohistochemical expression of estrogen receptor 
and progesterone receptor have prospectively been validated as independent prognosticators 
for lymph node metastasis and poor outcome [6]. Also, L1 cell adhesion molecule expression 
has retrospectively been validated in large cohorts as a strong preoperative prognosticator for 
high-risk features including non-endometrioid histology, LVSI, and poor outcome [33,34]. 
Until now, none of these biomarkers has been incorporated in standardized routine care. To 
optimize the clinical applicability of these immunohistochemical biomarkers, the combined 
value should further be elucidated. Furthermore, the prognostic value of immediate 
postoperative and follow-up CA-125 serum levels remains unclear, and future research should 
focus on the ability of follow-up CA-125 to detect recurrent disease.
Concluding, this study has shown that elevated CA-125 is an independent preoperative 
prognosticator for poor outcome in EC patients, even in patients identified as low-risk 
based on preoperative histology. Preoperative assessment of CA-125 could be an attractive 
additional tool, next to tumor histology and assessment of MI/tumor size in preoperative 
risk stratification. Patients with low-risk EC and elevated CA-125 represent a group with 
substantial risk of poor outcome and should be considered as high-risk endometrial 
carcinoma. Whether adjuvant treatment should be applied in these high-risk patients needs 
to be determined.
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